Sui launches Hong Kong-regulated gold token as SUI price falls below $1
Sui Network has introduced XAUa, a Hong Kong-regulated tokenized gold asset, to its blockchain ecosystem, extending its lineup of real-world assets even as its native cryptocurrency SUI faces continued downward pressure.
Sui Expands Real-World Asset Offerings With XAUa
The newly launched XAUa token is issued by AlphaTokenHQ and distributed through TBook, utilizing Sui’s Permissioned Asset Standard (PAS) for compliance. XAUa’s regulation under Hong Kong jurisdiction aims to broaden Sui’s appeal to institutions seeking compliant onchain assets, while also showing how blockchain platforms can host regulated, tokenized versions of traditional assets like gold.
Sui Network, known for its Layer 1 blockchain, has positioned itself as a hub for asset tokenization, enabling permissioned and regulated financial products to operate within its decentralized environment. By adhering to regulatory standards, Sui seeks to attract interest from institutional players and fintech projects exploring compliant digital asset offerings. However, the project’s latest announcement does not directly confirm increased demand or new capital inflows for SUI tokens themselves.
Mini dictionary: Permissioned Asset Standard (PAS) is a technical framework on Sui that enables projects to create regulated, permissioned tokens, including restrictions for compliance and authorized transfers.
“Hong Kong-regulated tokenized gold is live on Sui, minted with the Permissioned Asset Standard (PAS). XAUa is issued by AlphaTokenHQ and distributed onchain by TBook,” reported the Sui Network team.
SUI Price Struggles Below Key Technical Levels
Despite the introduction of XAUa, SUI’s price continues to reflect considerable selling pressure. As of the latest trading session, SUI was quoted at $0.9254, reflecting a 0.86% decrease over the past 24 hours. The token remains below its 50-day moving average of $0.9916, indicating that short-term sentiment remains weak. The 200-day moving average, currently at $0.8660, acts as a potential support level if the price continues its decline.
Technical analysis shows that the Relative Strength Index (RSI) measures 39.78, falling under its average but still above the oversold threshold. SUI’s price has failed to sustain its earlier September rally, which pushed it above $1.20 and close to $1.30 by early October. Following this peak, the token has retreated beneath the $1.00 psychological level.
Resistance is identified at $1.0119, while support is noted at $0.7849. A move above $1.0119 could indicate an improving outlook, while a loss of support at $0.7849 may expose SUI to further declines.
| 50-day moving average | $0.9916 |
| 200-day moving average | $0.8660 |
| Resistance | $1.0119 |
| Support | $0.7849 |
The launch of regulated gold tokens highlights Sui’s ambitions in real-world asset tokenization, yet current technical and volume trends suggest that SUI’s price remains under significant pressure until buyers reclaim critical resistance levels.
Trading Volume and Market Outlook
CoinGlass data indicates that SUI experienced a surge in trading volume during its September rally. However, volume has generally tapered off in October, with a brief increase around October 24. While the data show volatile conditions, it does not specify whether recent activity has been dominated by buyers or sellers.
Liquidation charts display notable long and short liquidation events during periods of sharp price swings, particularly in late September and early October. Specific data about current liquidations, open interest, or funding rates were not available, making it harder to gauge present derivatives sentiment.
Market observers note that a shift above the 50-day moving average and sustained price action over $1.0119 could boost the recovery narrative for SUI. On the downside, a break below $0.8660 and especially $0.7849 would likely signal deeper risk. The project’s tokenized gold launch is viewed as a positive milestone, but SUI’s short-term market prospects depend on renewed buying interest and external catalysts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
